Spots Global Cancer Trial Database for metastatic nasopharyngeal carcinoma
Every month we try and update this database with for metastatic nasopharyngeal carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma | NCT04627961 | Metastatic Naso... Recurrent Nasop... | TAS-102 | 21 Years - 99 Years | National University Hospital, Singapore | |
| Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma | NCT06331845 | Metastatic Naso... Intermittent Sy... | Gemcitabine Cisplatin Paclitaxel prot... Capecitabine Tislelizumab | 18 Years - 70 Years | Fujian Cancer Hospital | |
| A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma | NCT04627961 | Metastatic Naso... Recurrent Nasop... | TAS-102 | 21 Years - 99 Years | National University Hospital, Singapore | |
| Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma | NCT02250599 | Nasopharyngeal ... | Paclitaxel Bevacizumab Carboplatin | 18 Years - | Sun Yat-sen University | |
| Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | NCT06029270 | Metastatic Naso... Recurrent Nasop... Stage IV Nasoph... | Biospecimen Col... Bone Scan Carboplatin Cisplatin Computed Tomogr... Gemcitabine Magnetic Resona... Nivolumab Positron Emissi... Relatlimab | 18 Years - | National Cancer Institute (NCI) | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | NCT06029270 | Metastatic Naso... Recurrent Nasop... Stage IV Nasoph... | Biospecimen Col... Bone Scan Carboplatin Cisplatin Computed Tomogr... Gemcitabine Magnetic Resona... Nivolumab Positron Emissi... Relatlimab | 18 Years - | National Cancer Institute (NCI) | |
| Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | NCT04231864 | Epstein-Barr Vi... Metastatic Naso... Recurrent Nasop... Stage III Nasop... Stage IV Nasoph... Stage IVA Nasop... Stage IVB Nasop... | Durvalumab Epacadostat | 18 Years - | University of California, San Francisco | |
| Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. | NCT04405622 | Nasopharyngeal ... Recurrent Nasop... Metastatic Naso... Chemotherapy Ef... Immunotherapy | Toripalimab plu... | 18 Years - 70 Years | Sun Yat-sen University | |
| Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer | NCT04458909 | Metastatic Naso... Metastatic Naso... Metastatic Naso... Metastatic Naso... Nasopharyngeal ... Recurrent Nasop... Recurrent Nasop... Recurrent Nasop... Stage IV Nasoph... Stage IVA Nasop... Stage IVB Nasop... | Carboplatin Cisplatin Gemcitabine Nivolumab Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. | NCT04405622 | Nasopharyngeal ... Recurrent Nasop... Metastatic Naso... Chemotherapy Ef... Immunotherapy | Toripalimab plu... | 18 Years - 70 Years | Sun Yat-sen University | |
| Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study | NCT04872582 | Metastatic Naso... Chemotherapy Ef... | PD-1 Immune Che... | 18 Years - 70 Years | Sun Yat-sen University | |
| Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma | NCT02250599 | Nasopharyngeal ... | Paclitaxel Bevacizumab Carboplatin | 18 Years - | Sun Yat-sen University | |
| Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | NCT04231864 | Epstein-Barr Vi... Metastatic Naso... Recurrent Nasop... Stage III Nasop... Stage IV Nasoph... Stage IVA Nasop... Stage IVB Nasop... | Durvalumab Epacadostat | 18 Years - | University of California, San Francisco | |
| Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure | NCT04586088 | Nasopharyngeal ... Recurrent Nasop... Metastatic Naso... Chemotherapy Ef... Immunotherapy Molecular Targe... | Apatinib plus C... | 18 Years - 70 Years | Sun Yat-sen University | |
| Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. | NCT04405622 | Nasopharyngeal ... Recurrent Nasop... Metastatic Naso... Chemotherapy Ef... Immunotherapy | Toripalimab plu... | 18 Years - 70 Years | Sun Yat-sen University | |
| Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in | NCT05198479 | Metastatic Naso... | 77 Lu-DOTA0-Tyr... | 21 Years - 75 Years | National Cancer Centre, Singapore | |
| Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment | NCT05484375 | Metastatic Naso... | Capecitabine pl... | 18 Years - 65 Years | Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
